Numbers and news on vaccine efficacy and third dose. Gimbe Report
What emerges from the Gimbe foundation report on vaccine efficacy and third dose. Numbers, analyzes and scenarios
Although several studies now show that the effectiveness of vaccines decreases with increasing age, it remains high in preventing diagnoses with subsequent hospitalization, hospitalization or death. Both the Higher Institute of Health (ISS) and the Gimbe Foundation agree on this.
WHAT THE NUMBERS SAY
In particular, in the ISS report on the epidemiological situation in Italy we read that the preventive efficacy against hospitalizations is 91%, intensive care 95% and deaths 91%. The overall efficacy of complete vaccination in preventing infection in the period with dominant circulation of the alpha variant is 88.6%, while a reduction in overall efficacy is observed in the period with prevalent circulation of the delta variant (75.5% ).
HOW EFFECTIVE ARE VACCINES?
Observing the data of the Gimbe report, it is noted that the effectiveness of the vaccine on serious disease is confirmed to be very high and the incidence of diagnoses, hospitalizations, intensive care admissions and deaths is significantly lower in people vaccinated with a full cycle, in all groups. of age, compared to the unvaccinated.
However, particularly in the over 60s, the efficacy against severe disease is slightly but progressively decreasing, especially since the delta variant has become prevalent.
According to the latest report of the Integrated COVID-19 Surveillance of the Istituto Superiore di Sanità, for hospitalization in intensive care the effectiveness in the period 5 July-31 October is 90% in the over 80s and 94.8% in the 60-79 years, while for hospitalizations in the medical area 88.8% in the over 80s and 91.5% in the 60-79 age group.
"In reiterating the futility of measuring circulating antibodies for vaccination decision-making – commented the president of the Gimbe Foundation, Nino Cartabellotta – these data confirm the indications for the booster dose for the risk categories identified by the Ministry of Health and the need for accelerate its administration ".
ADDITIONAL DOSE AND BOOSTER DOSE
On November 3, 2,409,596 third doses were administered, including 383,769 additional doses and 2,025,827 booster doses. , with a 7-day moving average that exceeded 100,000.
The national vaccination coverage rate for additional doses is 40% with clear regional differences: from 2.3% in Valle D'Aosta to 100% in Umbria and Piedmont.
The national coverage with the booster dose is 39.5%, again with considerable differences between the Regions: from 18.3% in Calabria to 81.2% in Molise (figure 18).
ACCELERATE ON THE THIRD DOSES
Of the audience relating to the booster dose, stopped at the update of November 2, there are still over 3.1 million people to be vaccinated, to which every week there are about 800 thousand over 60 who have completed the vaccination cycle in the months of May and June.
That is, by the end of the year, 7.4 million people will be added to this audience, in addition to about 750,000 under 60 vaccinated with Johnson & Johnson by the end of June.
Overall, there are more than 11 million booster doses which require the Regions to make a decisive change of pace both in terms of communication and persuasion, and in terms of organization, given that by the end of December about 1.4 million doses per week should be administered.
VACCINES LOW
"With the increase in viral circulation that is reflected in hospitalizations, the gradual decline in vaccination efficacy and the small increase in new vaccinates – said Cartabellotta – the acceleration in terms of third doses is a fundamental strategy to contain the fourth wave. From this point of view, both the non-deliveries of vaccines for 4 weeks without official information on the supply plan, and some critical issues that hinder the monitoring of the performance of the Regions, which in fact go in no particular order, are starting to worry ".
WHO MISSES THE APPEAL
“First of all – continued the President of the Foundation – the audience that can be vaccinated with the third dose has not yet been officially extended to those under 60 who have received the Johnson & Johnson vaccine. Secondly, the audience for the booster dose is not constantly updated with the number of people who progressively reach 6 months from the completion of the vaccination cycle, with a consequent overestimation of regional performance. Finally, no details are available of the categories of vaccinated with dose boosters (health workers, RSA guests, over 60 and frail people), making it impossible to identify any regional criticalities ".
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/cosa-dice-report-gimbe-efficacia-vaccini-terza-dose/ on Thu, 11 Nov 2021 12:03:31 +0000.